Amy Xia

Vice President, Amgen Inc., USA

Keynote Speech (IV) 2025/December/18 (Thursday) 10:20 – 11:20

Amy Xia is Vice President, Center for Design and Analysis at Amgen (including Biostatics, Statistical Programming, Design & Innovation, Data Sciences, etc), providing leadership for strategic drug development and driving innovative program/study designs across Amgen's portfolios for evidence generation and decision-making. Amy has extensive experience in biopharmaceutical and medical device industries in the past two decades across all development phases and a variety of disease areas. Amy is a recognized industry expert in innovative Bayesian applications, adaptive designs, pediatric extrapolation, meta-analysis and safety evaluation in drug development, and pioneers work in design optimization, evidence synthesis and product/portfolio decision-making. She is currently a member of the ICH E20 Expert Working Group on Adaptive Clinical Trials and previously served as the Vice-Chair for the DIA Bayesian Scientific Working Group. Amy is an elected Fellow of American Statistical Association. She received her PhD in Biostatistics from the University of Minnesota.